Novartis AG
1NOVN
Company Profile
Business description
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Contact
Lichtstrasse 35
Basel4056
CHET: +41 613241111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,883
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,077.60 | 37.40 | 0.41% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,043.47 | 299.96 | -1.18% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 42,456.16 | 517.27 | 1.23% |
| NZX 50 Index | 13,128.19 | 53.38 | 0.41% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,809.90 | 42.60 | 0.49% |
| SSE Composite Index | 3,743.55 | 70.01 | -1.84% |